Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance.
Cancer Discov. 2022 Jun 2:candisc.1463.2021-11-2 01:32:02.600. doi: 10.1158/2159-8290.CD-21-1463. Online ahead of print.
Cancer Discov. 2022.
PMID: 35638972